2. Academic Validation
  3. Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers DS-103 as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties

Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers DS-103 as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties

  • J Med Chem. 2025 Feb 27;68(4):4426-4452. doi: 10.1021/acs.jmedchem.4c02373.
Daniel Stopper 1,  Lukas Biermann 2,  Paris R Watson 3,  Jingyu Li 2,  Beate König 1,  Matthew N Gaynes 3,  Lais Pessanha de Carvalho 4,  Jana Klose 5,  Maria Hanl 1,  Alexandra Hamacher 2,  Linda Schäker-Hübner 1,  Daniel Ramsbeck 5,  Jana Held 4 6 7,  David W Christianson 3,  Matthias U Kassack 2,  Finn K Hansen 1
Affiliations

Affiliations

  • 1 Department of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, 53121 Bonn, Germany.
  • 2 Institute of Pharmaceutical and Medicinal Chemistry, University of Düsseldorf, 40225 Düsseldorf, Germany.
  • 3 Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States.
  • 4 Institute of Tropical Medicine, University of Tübingen, 72074 Tübingen, Germany.
  • 5 Department of Applied Biosciences and Process Technology, Anhalt University of Applied Sciences, 06366 Köthen, Germany.
  • 6 German Center for Infection Research, Partner Site Tübingen, 72074 Tübingen, Germany.
  • 7 Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon.
PMID: 39946728 DOI: 10.1021/acs.jmedchem.4c02373
Abstract

In this work, we synthesized a series of peptoid-based histone deacetylase (HDAC) inhibitors with variations in the linker region and zinc-binding groups. All compounds were investigated for their HDAC inhibition, antiplasmodial activity, and cytotoxicity against native and cisplatin-resistant carcinoma cell lines. The ethylhydrazide 20 (DS-103) proved to be the most effective compound in these primary screenings. DS-103 showed nanomolar inhibition of class I HDACs and of HDAC6 (class IIb). To further investigate the binding mode of DS-103, a crystal structure of DS-103 in complex with HDAC6 was obtained, which represents the first reported crystal structure of an alkylhydrazide in complex with an HDAC Enzyme. Importantly, DS-103 completely reversed cisplatin resistance in two different platinum-resistant solid Cancer cell lines and demonstrated strong synergism with cisplatin. The synergistic Anticancer effects are mediated by increased DNA damage and p21 expression, resulting in caspase-mediated Apoptosis and cell death.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z